Review
Accepted on 03 Oct 2025
PDE10A as a Novel Diagnostic and Therapeutic Target in Cancer: Insights and Challenges
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1669157
- 126 views
Type at least 3 characters
1,995 articles
Brief Research Report
Accepted on 03 Oct 2025
Immunohistochemical Analysis of Enolase-1 Sublocalization in Benign and Malignant Breast Tumors: Potential Implications for Tumor Progression and Prognosis
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1636394
- 118 views
Review
Published on 03 Oct 2025
Potential immunogenic modulation of hypo-fractionated radiotherapy at optimal schedules and the subsequent vaccine-like effect of local irradiation - a systematic review
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1546875
- 393 views
Mini Review
Published on 03 Oct 2025
The role of apelin in cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1683865
- 511 views
Case Report
Published on 02 Oct 2025
Pathologic complete response of advanced hepatoid adenocarcinoma of the stomach following immuno-chemotherapy and conversion surgery: a rare case report and review of the literature
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1648766
- 598 views
Editorial
Accepted on 01 Oct 2025
Editorial: Renewed Insight into Cancer Mechanism and Therapy
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1710803
- 162 views
Review
Published on 01 Oct 2025
Comparing the risk of cardiovascular disease between degarelix and gonadotropin-releasing hormone agonists:a systematic review and meta-analysis
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1523794
- 1,002 views
Case Report
Accepted on 30 Sep 2025
Trametinib in the treatment of patients with metastatic lung adenocarcinoma harboring NF1 mutation: a case series and literature review
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1481284
- 849 views
Original Research
Accepted on 30 Sep 2025
A phase Ib/II study of modakafusp alfa alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1620987
- 247 views
Original Research
Published on 25 Sep 2025
Prognostic impact of miR-17-5p and miR-20a-5p in NSCLC diverge in subgroups according to lymph node status
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1606933
- 1,036 views
Original Research
Accepted on 24 Sep 2025
Integrated machine learning-based establishment of a prognostic model in multicenter cohorts for acute myeloid leukemia
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1649594
- 620 views
Correction
Published on 24 Sep 2025
Correction: Application and development of Organ-on-a-Chip technology in cancer therapy
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1703677
- 1,229 views
Correction
Published on 23 Sep 2025
Correction: Editorial: Current status and recent advances in preclinical models for rare cancers
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1697286
- 720 views
Original Research
Published on 23 Sep 2025
Mechanistic studies of miR-582-3p targeting of PTPRCAP affecting lung adenocarcinoma via the Wnt/β-catenin pathway
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1652176
- 1,105 views
Original Research
Accepted on 22 Sep 2025
Construction of a Prognostic Model for Colorectal Cancer Liver Metastasis Based on Single-Cell Transcriptomics and Regulation of the MIF Pathway
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1588514
- 359 views
Original Research
Accepted on 22 Sep 2025
Downregulation of SALL1 and Its Association with Poor Prognosis and the Immune Cell Landscape in Clear Cell Renal Cell Carcinoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1624651
- 292 views